Seeking Alpha

Snowboard 2k01

Snowboard 2k01
Send Message
View as an RSS Feed
View Snowboard 2k01's Comments BY TICKER:
Latest  |  Highest rated
  • Axion Power Concentrator 394: Apr. 2, 2015 [View instapost]

    So are you OMY?
    Apr 8, 2015. 07:34 PM | 5 Likes Like |Link to Comment
  • A Close-Up Look At The Report That Had MannKind Investors Reeling [View article]

    Shorts have increased.

    2/27/2015 90,734,471

    Float 261.30M
    Mar 12, 2015. 02:03 PM | Likes Like |Link to Comment
  • MannKind: Use This Drop As An Opportunity [View article]
    Mr Olson is well aware of the positive attributes of Afrezza and like our present National Security Adviser knowingly did the latter, instructed by their superiors.
    Mar 4, 2015. 09:03 AM | 7 Likes Like |Link to Comment
  • More Insight Into MannKind's Near-Term Profitability [View article]
    "Mannkind needs to borrow money from Al and buy back those bonds, they just need 7 more days to do it...yeah Matt were counting."

    They need or only have 7 more days to do it.

    Please explain.
    Feb 26, 2015. 08:07 AM | Likes Like |Link to Comment
  • More Insight Into MannKind's Near-Term Profitability [View article]
    "significant profits look to be many years away".
    "Pfeffer stated that the current factory capacity allows it to manufacture between 100 to 120 million cartridges a year."

    I believe the Ultimate capacity of Danbury is 20 times the above figure and will be arrived at next year.

    "This suggests that the progress payments will go into the expenses of building out the factory and will only turn into profit when Sanofi purchases, at cost, the insulin the new factory lines produce."

    The expense of building out is figured into the "cost of goods" over time.
    Feb 25, 2015. 05:02 PM | 2 Likes Like |Link to Comment
  • Axion Power Concentrator 389: Feb. 12, 2015 [View instapost]
    Doug Speece of Axion Power E-mailed me a 17 page PDF, to integrate into a proposal combining our Solar canopy with their battery system.

    He might send it to you
    Feb 17, 2015. 08:28 AM | 6 Likes Like |Link to Comment
  • Axion Power Concentrator 389: Feb. 12, 2015 [View instapost]
    What is the "PbCBattery Energy Storage System Installation"
    pictured in and around Albany NY in Axion's 11-112014 Web presentation?
    Feb 16, 2015. 06:11 PM | 3 Likes Like |Link to Comment
  • Cleveland BioLabs Announces Expansion of Entolimod Patent Portfolio With New Composition of Matter Patents [View article]

    Did you listen to the webcast from yesterday?

    BUFFALO, NY--(Marketwired - Feb 5, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the 2015 BIO CEO & Investor Conference, February 9-10, in New York, NY.
    Yakov Kogan, Ph.D., Chief Executive Officer of Cleveland BioLabs, will present the Company's oncology and biodefense programs on February 10 at 2:00 p.m. ET. A live and archived webcast of the Company's presentation will be available on the investor page of the Cleveland BioLabs website.
    By enlarging the slide show and listing to Dr Kogan the presentation is understandable.
    All testing is done for the EUA (Emergency Use Authorization). Submission electronically to the FDA this spring was mentioned and a response in months expected.
    DOD can then purchase for stockpiling.
    I believe Israel will purchase $140,000,000 worth this year. And reorder every three years.
    Feb 12, 2015. 10:05 AM | Likes Like |Link to Comment
  • Axion Power Concentrator 388: Jan. 31, 2015 [View instapost]
    Was much testing done as a yard slug and if so how did it go?
    Feb 9, 2015. 10:58 AM | 3 Likes Like |Link to Comment
  • Axion Power Concentrator 387: Jan. 25, 2015 [View instapost]
    I'm looking for data on pay back using frequency regulation using Axion for a solar install. I would like information on how hard it would be to have Wind and Solar imputes.

    I'm Going on Eight Years here I RI with MY Saturn Vue Greenline Hi-bred. Car is never garaged and both original batteries are functioning.
    Jan 30, 2015. 11:39 AM | 2 Likes Like |Link to Comment
  • Long-Term Growth Prospects Of SandRidge Remain Intact [View article]
    The decrease was 90% or so do to the divestiture of the Gulf of Mexico properties among others.

    How does crap like this get published Seeking Alpha?
    Aug 16, 2014. 08:22 AM | 2 Likes Like |Link to Comment
  • Properly Treating Costs: Re-Evaluating The MannKind And Sanofi Partnership [View article]
    Nice of Matt to go on Vacation and leave us hanging.

    Sanofi is contributing a sales force that would soon be out of work if not for Afrezza, even more so if a competitor had partnered with Mannkind.
    Aug 14, 2014. 11:22 AM | 1 Like Like |Link to Comment
  • Why The Sanofi Deal Is The Best Possible Deal For MannKind Investors [View article]
    "But to put this in perspective, to get 35% of the profits of Afrezza--after being paid at cost for producing Afrezza--and getting three quarters of a billion dollars as milestones are met outside of the money from the royalty sounds to me like a fabulous deal. Because Sanofi can and WILL sell this drug like no other company could."

    I still can't get a straight answer.

    Is Mannkind's up to now investment of over $1Billon , Building Danbury and all the past 10 years of R&D going to be included in the "Cost of the product" sold to Sanofi at "cost"? If so how is that figured and is that separate from the milestone payments?
    Aug 13, 2014. 12:49 PM | 1 Like Like |Link to Comment
  • Update: MannKind Q2 Earnings - Stock Sent To The Woodshed [View article]
    Mannkind will claw back a good portion of that " 2B spent getting approval" incorporating it into the cost of the Afrezza that it sells to Sanofi "at cost".

    The only way Sanofi makes money is to sell a lot of Afrezza.

    So over the net five years Mannkind may get all the milestones + recoup their close to $2billion investment.

    If Danbury can't meet all the production needs, the partnership will collaborate on new facilities. Those costs will become part of the cost of the product.

    Aug 13, 2014. 10:52 AM | 3 Likes Like |Link to Comment
  • A Deeper Look At MannKind - Sanofi Deal And Valuation [View article]
    Sanofi pays Mannkind cost for the finished product Afrezza.

    That cost includes most past expense Mannkind incurred developing the drug which is well over One Billion Dollars. Any new facility in the future will be part of the cost of the product.
    Aug 13, 2014. 10:34 AM | Likes Like |Link to Comment